Скачайте изображение (превью) выбрав качество

320x180 480x360 640x480 1280x720

Visit Radcliffe Cardiology:

Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Prof Alexandre Mebazaa (University Hospitals Saint Louis‐Lariboisière, FR), the primary investigator of the anticipated STRONG-HF Trial.

This study aimed to evaluate the safety and efficacy of rapid-optimization heart failure therapies. 1800 patients were randomized to receive either usual care or high-intensity care; with high-intensity care defined as an intensification of treatment with a beta-blocker, a renin-angiotensin system blocker, and a mineralocorticoid receptor blocker. Safety signals for heart failure were also assessed, and biomarkers and lab measures were frequently measured.

STRONG-HF was terminated early by the data safety monitoring board (DSMB) due to a significantly lower risk of the primary endpoint in the high-intensity care arm as compared to the usual care arm.

Recorded remotely from Hamilton and Paris, 2022.
This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Чтобы скачать видео "AHA 22: Late-Breaker Discussion: The STRONG-HF Trial" передвинте ползунок вправо